{"title":"[大鼠肝脏S9组分中瑞香素的体外代谢研究]。","authors":"Si-cheng Liang, Guang-bo Ge, Yang-liu Xia, Xiao-yi Qi, Ao-xue Wang, Cai-xia Tu, Ling Yang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Daphnetin is quickly eliminated in rats after dosing, but the mechanism remains unclear. This\nstudy was aimed to investigate the in vitro metabolism of daphnetin using rat liver S9 fractions (RLS9). The\nmetabolites formed in RLS9 were identified and the kinetic parameters for different metabolic pathways\nwere determined. HPLC-DAD-MS analysis showed that daphnetin was biotransformed to six metabolites,\nwhich were identified as 7 or 8 mono-glucuronide and mono-sulfate, 8-methylate, and 7-suflo-8-methylate.\nMethylation and glucuronidation of daphnetin exhibited the Michaelis-Menten kinetic characteristics, whereas\nthe substrate inhibition kinetic and the two-site kinetic were observed for 8-sulfate and 7-sulfate formations. Of\nthe 3 conjugation pathways, the intrinsic clearance rate for sulfation was highest, followed by methylation and\nglucuronidation. By in vitro-in vivo extrapolation of the kinetic data measured in RLS9, the hepatic clearance\nwere estimated to be 54.9 mL·min−1·kg−1 which is comparable to the system clearance (58.5 mL·min−1·kg−1)\nobserved in rats. In conclusions, the liver might be the main site for daphnetin metabolism in rats. Sulfation,\nmethylation and glucuronidation are important pathways of the hepatic metabolism of daphnetin in rats.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"52 2","pages":"291-5"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[In vitro metabolism of daphnetin in rat liver S9 fractions].\",\"authors\":\"Si-cheng Liang, Guang-bo Ge, Yang-liu Xia, Xiao-yi Qi, Ao-xue Wang, Cai-xia Tu, Ling Yang\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Daphnetin is quickly eliminated in rats after dosing, but the mechanism remains unclear. This\\nstudy was aimed to investigate the in vitro metabolism of daphnetin using rat liver S9 fractions (RLS9). The\\nmetabolites formed in RLS9 were identified and the kinetic parameters for different metabolic pathways\\nwere determined. HPLC-DAD-MS analysis showed that daphnetin was biotransformed to six metabolites,\\nwhich were identified as 7 or 8 mono-glucuronide and mono-sulfate, 8-methylate, and 7-suflo-8-methylate.\\nMethylation and glucuronidation of daphnetin exhibited the Michaelis-Menten kinetic characteristics, whereas\\nthe substrate inhibition kinetic and the two-site kinetic were observed for 8-sulfate and 7-sulfate formations. Of\\nthe 3 conjugation pathways, the intrinsic clearance rate for sulfation was highest, followed by methylation and\\nglucuronidation. By in vitro-in vivo extrapolation of the kinetic data measured in RLS9, the hepatic clearance\\nwere estimated to be 54.9 mL·min−1·kg−1 which is comparable to the system clearance (58.5 mL·min−1·kg−1)\\nobserved in rats. In conclusions, the liver might be the main site for daphnetin metabolism in rats. Sulfation,\\nmethylation and glucuronidation are important pathways of the hepatic metabolism of daphnetin in rats.</p>\",\"PeriodicalId\":35924,\"journal\":{\"name\":\"药学学报\",\"volume\":\"52 2\",\"pages\":\"291-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药学学报\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[In vitro metabolism of daphnetin in rat liver S9 fractions].
Daphnetin is quickly eliminated in rats after dosing, but the mechanism remains unclear. This
study was aimed to investigate the in vitro metabolism of daphnetin using rat liver S9 fractions (RLS9). The
metabolites formed in RLS9 were identified and the kinetic parameters for different metabolic pathways
were determined. HPLC-DAD-MS analysis showed that daphnetin was biotransformed to six metabolites,
which were identified as 7 or 8 mono-glucuronide and mono-sulfate, 8-methylate, and 7-suflo-8-methylate.
Methylation and glucuronidation of daphnetin exhibited the Michaelis-Menten kinetic characteristics, whereas
the substrate inhibition kinetic and the two-site kinetic were observed for 8-sulfate and 7-sulfate formations. Of
the 3 conjugation pathways, the intrinsic clearance rate for sulfation was highest, followed by methylation and
glucuronidation. By in vitro-in vivo extrapolation of the kinetic data measured in RLS9, the hepatic clearance
were estimated to be 54.9 mL·min−1·kg−1 which is comparable to the system clearance (58.5 mL·min−1·kg−1)
observed in rats. In conclusions, the liver might be the main site for daphnetin metabolism in rats. Sulfation,
methylation and glucuronidation are important pathways of the hepatic metabolism of daphnetin in rats.
药学学报Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍:
Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.